FI952248A0 - Kasvainvastaisia koostumuksia, jotka sisältävät taksaanijohdannaisia - Google Patents

Kasvainvastaisia koostumuksia, jotka sisältävät taksaanijohdannaisia

Info

Publication number
FI952248A0
FI952248A0 FI952248A FI952248A FI952248A0 FI 952248 A0 FI952248 A0 FI 952248A0 FI 952248 A FI952248 A FI 952248A FI 952248 A FI952248 A FI 952248A FI 952248 A0 FI952248 A0 FI 952248A0
Authority
FI
Finland
Prior art keywords
esp
derivatives
synthetic
compositions containing
taxane derivatives
Prior art date
Application number
FI952248A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI952248A (fi
Inventor
Marie-Christine Bissery
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9435406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI952248(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI952248A0 publication Critical patent/FI952248A0/fi
Publication of FI952248A publication Critical patent/FI952248A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI952248A 1992-11-10 1995-05-09 Kasvainvastaisia koostumuksia, jotka sisältävät taksaanijohdannaisia FI952248A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9213525A FR2697752B1 (fr) 1992-11-10 1992-11-10 Compositions antitumorales contenant des dérivés du taxane.
PCT/FR1993/001096 WO1994010995A1 (fr) 1992-11-10 1993-11-08 Compositions antitumorales contenant des derives du taxane

Publications (2)

Publication Number Publication Date
FI952248A0 true FI952248A0 (fi) 1995-05-09
FI952248A FI952248A (fi) 1995-05-09

Family

ID=9435406

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952248A FI952248A (fi) 1992-11-10 1995-05-09 Kasvainvastaisia koostumuksia, jotka sisältävät taksaanijohdannaisia

Country Status (25)

Country Link
US (13) US5728687A (pl)
EP (4) EP1295597A1 (pl)
JP (1) JP3974938B2 (pl)
KR (2) KR20030096445A (pl)
AT (2) ATE205083T1 (pl)
AU (1) AU680845B2 (pl)
CA (1) CA2149055C (pl)
CZ (2) CZ288033B6 (pl)
DE (2) DE69318033T2 (pl)
DK (2) DK0667771T3 (pl)
ES (2) ES2163076T3 (pl)
FI (1) FI952248A (pl)
FR (1) FR2697752B1 (pl)
GR (2) GR3026666T3 (pl)
HU (1) HU223773B1 (pl)
MX (1) MX9306924A (pl)
NO (1) NO315027B1 (pl)
NZ (1) NZ257585A (pl)
PL (1) PL173951B1 (pl)
PT (1) PT827745E (pl)
RU (1) RU2131250C1 (pl)
SK (1) SK282867B6 (pl)
TW (1) TW386877B (pl)
WO (1) WO1994010995A1 (pl)
ZA (1) ZA938182B (pl)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US6441026B1 (en) 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6011069A (en) * 1995-12-26 2000-01-04 Nisshin Flour Milling Co., Ltd. Multidrug resistance inhibitors
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6667053B1 (en) * 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
WO1997030174A1 (en) * 1996-02-20 1997-08-21 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US7371376B1 (en) * 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US5811452A (en) * 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6740497B2 (en) * 1998-03-06 2004-05-25 The Regents Of The University Of California Method and apparatus for detecting cancerous cells using molecules that change electrophoretic mobility
US6335201B1 (en) * 1998-03-06 2002-01-01 The Regents Of The University Of California Method and apparatus for detecting enzymatic activity using molecules that change electrophoretic mobility
KR20010021656A (ko) * 1998-03-27 2001-03-15 로렌스 티. 마이젠헬더 정맥내 에스트라무스틴 포스페이트의 효력 상승 방법
US6849616B1 (en) 1998-03-27 2005-02-01 Pharmacia Italia S.P.A. Methods to potentiate intravenous estramustine phosphate
DE69931766T2 (de) * 1998-04-03 2007-05-31 Ajinomoto Co., Inc. Antitumorale mittel
WO1999056742A1 (en) * 1998-05-04 1999-11-11 Auckland Uniservices Limited Chemotherapeutic treatment
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
WO2000006134A2 (en) * 1998-07-30 2000-02-10 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
GB9904386D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1181013B1 (en) * 1999-04-14 2006-10-11 Dana-Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
US20050222246A1 (en) * 1999-04-14 2005-10-06 Li Chiang J Beta-lapachone is a broad spectrum anti-cancer agent
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
US6737240B1 (en) * 1999-05-25 2004-05-18 Rigel Pharmaceuticals, Inc. Methods of screening for a multi-drug resistance conferring peptide
JP4579471B2 (ja) * 1999-06-25 2010-11-10 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
ATE437655T1 (de) * 1999-06-25 2009-08-15 Genentech Inc Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
KR20090024308A (ko) * 1999-08-27 2009-03-06 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
RU2264400C2 (ru) 2000-02-02 2005-11-20 Флорида Стейт Юниверсити Рисерч Фаундейшн, Инк. Таксан, фармацевтическая композиция на его основе и способ ингибирования роста опухоли
US6362217B2 (en) * 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
EP1276756A4 (en) * 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
AU2001259271A1 (en) * 2000-04-28 2001-11-12 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
JP2003534292A (ja) * 2000-05-19 2003-11-18 ジェネンテック・インコーポレーテッド Ｅｒｂｂアンタゴニスト癌治療に対する有効な応答の可能性を向上させるための遺伝子検出アッセイ
US6541509B2 (en) * 2000-09-15 2003-04-01 Albert Einstein College Of Medicine Of Yeshiva University Method for treating neoplasia using combination chemotherapy
HUP0302599A3 (en) 2000-09-22 2005-05-30 Bristol Myers Squibb Co Method for reducing toxicity of combined chemotherapic compositions
CZ20031327A3 (cs) * 2000-11-06 2003-11-12 Pharma Mar, S. A. Užití ET-743 k výrobě léků pro účinnou protinádorovou léčbu
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
RU2178702C1 (ru) * 2001-02-21 2002-01-27 Общество с ограниченной ответственностью "Нобель" Антираковое средство
US6703400B2 (en) * 2001-02-23 2004-03-09 Schering Corporation Methods for treating multidrug resistance
EP1368034A1 (en) * 2001-03-06 2003-12-10 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
JP2004529904A (ja) * 2001-03-14 2004-09-30 ブリストル−マイヤーズ　スクイブ　カンパニー 増殖性疾患の治療のためのエポシロン類似体および化学療法剤の組み合わせ
AU2002255810A1 (en) * 2001-03-20 2002-10-03 New Century Pharmaceuticals, Inc. Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
UY27220A1 (es) * 2001-03-23 2002-09-30 Aventis Pharma Sa Combinación de un taxano con una quinasa ciclina-dependiente
CA2446739A1 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
US6924312B2 (en) 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
EP1293205A1 (en) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
US20040191218A1 (en) * 2001-09-26 2004-09-30 Emlen James W Pharmaceutical compositions and methods for treating cancer
CA2462502A1 (en) * 2001-10-19 2003-05-15 Pharma Mar, S.A. Improved use of antitumoral compound in cancer therapy
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
ES2545090T3 (es) * 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US6816571B2 (en) * 2002-02-06 2004-11-09 L-3 Communications Security And Detection Systems Corporation Delaware Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
US7426479B2 (en) * 2002-03-12 2008-09-16 Ncr Corporation Customer activity data system and method
US6593334B1 (en) * 2002-05-02 2003-07-15 The University Of North Carolina At Chapel Hill Camptothecin-taxoid conjugates as antimitotic and antitumor agents
CN1652845A (zh) * 2002-05-17 2005-08-10 安万特医药股份有限公司 多西他赛/阿霉素/环磷酰胺在辅助治疗乳腺癌和卵巢癌中的用途
ATE485818T1 (de) * 2002-07-30 2010-11-15 Karykion Inc Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
JP2006516117A (ja) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
US20040229931A1 (en) * 2003-04-30 2004-11-18 Aventis Pharma S. A. 1-Aryl-3-(indol-5-yl) prop-2-en-1-ones, compositions containing them and use
CA2526278A1 (en) * 2003-05-20 2004-12-02 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
CA2544320A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
CN1897949A (zh) * 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
US20050192247A1 (en) * 2004-02-23 2005-09-01 Li Chiang J. Method of treating cancers
US20060035907A1 (en) * 2004-02-23 2006-02-16 Christensen James G Methods of treating abnormal cell growth using c-MET and m-TOR inhibitors
EP2305642A3 (en) 2004-06-23 2011-12-14 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
CN101068596A (zh) * 2004-09-29 2007-11-07 法马马私人股份有限公司 艾可特耐思地作抗炎药
SI1827500T1 (sl) * 2004-10-26 2009-10-31 Pharma Mar Sa Pegiliran liposomski doksorubicin v kombinaciji s ekteinescidinom 743
SI1658848T1 (sl) 2004-10-29 2007-12-31 Pharma Mar Sa Formulacije vsebujoäśe ekteinascidin in disaharid
EP1827410A2 (en) 2004-11-19 2007-09-05 Synta Pharmaceuticals Corporation Bis(thio-hydrazide amides) for increasing hsp70 expression
EP1819349A2 (en) * 2004-11-22 2007-08-22 King Pharmaceuticals Research and Development Inc. Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
KR101914254B1 (ko) * 2005-02-18 2018-11-02 아브락시스 바이오사이언스, 엘엘씨 치료제의 조합 및 투여 방식, 및 조합 요법
JP5238936B2 (ja) * 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
CA2604907A1 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
US7709683B2 (en) 2005-05-16 2010-05-04 Synta Pharmaceuticals Corp. Synthesis of bis(thio-hydrazide amide) salts
AU2006255125B2 (en) * 2005-06-07 2011-12-08 Yale University Methods of treating cancer and other conditions or disease states using LFMAU and LDT
NZ565996A (en) 2005-08-16 2011-04-29 Synta Pharmaceuticals Corp Bis(thio-hydrazide amide) formulation
WO2007038792A2 (en) * 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
EP1942937A1 (en) * 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
WO2007054550A1 (en) 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
CA2645095A1 (en) * 2006-03-08 2007-09-13 University Of Maryland, Baltimore Inhibition of microtubule protrusion in cancer cells
CA2652926A1 (en) * 2006-05-26 2007-12-06 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer
AU2007288338B2 (en) 2006-08-21 2012-05-03 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
AU2007290490B2 (en) 2006-08-31 2011-09-08 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
WO2008033494A2 (en) 2006-09-15 2008-03-20 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
BRPI0717586A2 (pt) * 2006-09-18 2013-10-29 Boehringer Ingelheim Int Método para tratar câncer apresentando mutações do egfr
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
US20090093538A1 (en) * 2007-01-03 2009-04-09 Synta Pharmaceuticals Corp Method for treating cancer
JP5932217B2 (ja) 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Ｇｉｔｒ結合分子を使用する併用療法
AU2008313634A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
WO2011003853A2 (en) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CA3169263A1 (en) 2012-11-13 2014-05-22 Astellas Pharma Inc. Agents for treatment of claudin expressing cancer diseases
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
IL295906A (en) 2014-03-21 2022-10-01 Abbvie Inc Antibodies against egfr and drug antibody conjugates
WO2015191576A1 (en) 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
EP3469000A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP3468598A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
TWI762487B (zh) 2016-06-08 2022-05-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
WO2017214458A2 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
RU2680834C1 (ru) * 2018-05-23 2019-02-28 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Противоопухолевая композиция доксорубицина с ингибитором АТФ-зависимых обратных транспортеров клеток
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206221A (en) 1979-01-03 1980-06-03 The United States Of America As Represented By The Secretary Of Agriculture Cephalomannine and its use in treating leukemic tumors
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US4876399A (en) * 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
FR2623089B1 (fr) * 1987-11-13 1990-04-27 Pf Medicament Composition pharmaceutique pour l'administration parenterale de navelbine
GB8806224D0 (en) 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
US5015744A (en) * 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
AU2005692A (en) * 1991-05-08 1992-12-21 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
US5284864A (en) * 1991-09-23 1994-02-08 Florida State University Butenyl substituted taxanes and pharmaceutical compositions containing them
US5229526A (en) * 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5262409A (en) * 1991-10-11 1993-11-16 Fred Hutchinson Cancer Research Center Binary tumor therapy
US5294737A (en) * 1992-02-27 1994-03-15 The Research Foundation State University Of New York Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5254580A (en) 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
US5495501A (en) * 1992-09-02 1996-02-27 Fujitsu Limited Communication system including a digital roll-off filter
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5814658A (en) 1992-12-09 1998-09-29 Rhone-Poulenc Rorer S.A. Taxoids, their preparation and pharmaceutical compositions containing them
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
IL107950A (en) 1992-12-15 2001-04-30 Upjohn Co b 7, b 8 - Matano - Taxols, their preparation and pharmaceutical preparations against malignant tumors containing them
US6441026B1 (en) 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
EP0738253B1 (en) 1993-12-03 2001-09-05 Infineum USA L.P. Carbonyl containing compounds
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP0982028A1 (en) 1998-08-20 2000-03-01 Aventis Pharma S.A. New use of taxoid derivatives
EP1181013B1 (en) * 1999-04-14 2006-10-11 Dana-Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
US7696923B2 (en) * 2005-02-03 2010-04-13 Mexens Intellectual Property Holding Llc System and method for determining geographic location of wireless computing devices

Also Published As

Publication number Publication date
NO951327L (no) 1995-04-05
US20050226940A1 (en) 2005-10-13
EP1295597A1 (fr) 2003-03-26
DK0827745T3 (da) 2001-11-19
FR2697752B1 (fr) 1995-04-14
US20040152643A1 (en) 2004-08-05
ES2163076T3 (es) 2002-01-16
ATE165002T1 (de) 1998-05-15
JP3974938B2 (ja) 2007-09-12
GR3036537T3 (en) 2001-12-31
HU223773B1 (hu) 2005-01-28
DE69318033D1 (de) 1998-05-20
EP0827745A1 (fr) 1998-03-11
GR3026666T3 (en) 1998-07-31
PL173951B1 (pl) 1998-05-29
NO315027B1 (no) 2003-06-30
US6239167B1 (en) 2001-05-29
PL308902A1 (en) 1995-09-04
KR950703945A (ko) 1995-11-17
KR100334051B1 (ko) 2002-09-04
US8101652B2 (en) 2012-01-24
SK282867B6 (sk) 2003-01-09
HUT72499A (en) 1996-05-28
CA2149055A1 (fr) 1994-05-26
US7989489B2 (en) 2011-08-02
EP1093811A1 (fr) 2001-04-25
DK0667771T3 (da) 1998-10-07
WO1994010995A1 (fr) 1994-05-26
DE69330724D1 (de) 2001-10-11
ES2114620T3 (es) 1998-06-01
US20040013660A1 (en) 2004-01-22
US8124650B2 (en) 2012-02-28
TW386877B (en) 2000-04-11
ZA938182B (en) 1994-06-09
HU9501372D0 (en) 1995-06-28
FR2697752A1 (fr) 1994-05-13
CZ119395A3 (en) 1995-10-18
JPH08503205A (ja) 1996-04-09
CA2149055C (fr) 2003-01-07
US7994212B2 (en) 2011-08-09
EP0827745B1 (fr) 2001-09-05
KR20030096445A (ko) 2003-12-31
US5728687A (en) 1998-03-17
ATE205083T1 (de) 2001-09-15
US20020197245A1 (en) 2002-12-26
PT827745E (pt) 2002-02-28
US20040157786A1 (en) 2004-08-12
US20040152642A1 (en) 2004-08-05
MX9306924A (es) 1994-05-31
AU5425394A (en) 1994-06-08
EP0667771B1 (fr) 1998-04-15
CZ290120B6 (cs) 2002-06-12
NO951327D0 (no) 1995-04-05
FI952248A (fi) 1995-05-09
AU680845B2 (en) 1997-08-14
NZ257585A (en) 1996-06-25
US5908835A (en) 1999-06-01
US20040152644A1 (en) 2004-08-05
SK59595A3 (en) 1996-05-08
EP0667771A1 (fr) 1995-08-23
RU2131250C1 (ru) 1999-06-10
DE69330724T2 (de) 2002-07-11
CZ288033B6 (cs) 2001-04-11
DE69318033T2 (de) 1998-10-22
US20110263522A1 (en) 2011-10-27
US6214863B1 (en) 2001-04-10
US20040152673A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
FI952248A (fi) Kasvainvastaisia koostumuksia, jotka sisältävät taksaanijohdannaisia
RU95112842A (ru) Противоопухолевая композиция, содержащая производные таксана
HK1155944A1 (en) W-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
BG102879A (en) Carbolin derivatives
EP1140840A4 (en) DIPHENYLUREA WITH SUBSTITUENTS -G (V) -CARBOXYARYLES, INHIBITORS OF RAF KINASE
CA2315647A1 (en) Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas
RU93004649A (ru) Производные таксана, способ их получения и использование в онкологии,фармкомпозиция
GR3019871T3 (en) Taxane derivatives, their preparation and use in oncology
MX9706231A (es) Derivados de 2-aminobenzazapina.
IL157992A (en) Pharmacological preparations containing Texas
FI94037B (fi) Puun käsittelyseos ja -menetelmä
IL84261A (en) Pharmaceutical compositions comprising a 2,4-diphenyl 1,3-dioxane derivative and a thromboxane a2 synthetase inhibitor
AU5857899A (en) Use of tgf-beta inhibitors for treating cerebral disorders
CA2360676A1 (en) A method for treating patients with acne by administering a cyclic gmp pde inhibitor
CA2156908A1 (en) C9 taxane derivatives and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FC Application refused